Supplementary Material for: Effect of Interleukin-2 Receptor Antibody Induction Therapy on Survival in Renal Transplant Patients Receiving Tacrolimus

Background: This study aims to assess outcomes of interleukin-2 (IL-2) receptor blocker induction therapy on allograft and patients’ outcomes in standard risk recipients in the tacrolimus era, analysing data form the British Renal Transplant Registry. Methods: The study population involved all standard-risk renal transplant patients from 2000 till 2015 who were registered in the UK transplant registry and followed up till May 2018. Standard risk transplants were defined as patients with Results: In all, 3,597 renal transplant patients were included in the study. Two groups were identified; induction group (n = 2,858) which included patients who received IL-2 receptor blocker induction therapy and the no-induction group (n = 739). There was no significant difference between both groups in terms of estimated glomerular filtration rate (eGFR) rate at 1-year post-transplant (correlation co-efficient = 1.224, 95% CI ranges from –0.347 to 2.796). Average eGFR was 59.922 mL/min/1.73 m2 in the induction group (SD 29.171) and 64.557 mL/min/1.73 m2 in the no-induction groups (SD 46.763). There was no significant difference between both groups regarding graft survival at 5 years post-transplant (hazard ratio [HR] 0.944, 95% CI ranges from 0.599 to 1.485, p = 0.804), patient survival at 5 years post-transplant (HR 0.809, 95% CI ranges from 0.477 to1.372, p = 0.433). Conclusion: In the standard risk renal transplant population, the IL2 receptor blocker induction regimen does not affect eGFR at 1 year or renal and graft outcomes at 5 years.

研究背景：本研究旨在评估他克莫司（tacrolimus）时代下，白细胞介素-2（interleukin-2, IL-2）受体拮抗剂免疫诱导治疗对标准风险肾移植受者的移植物及患者预后的影响，分析来自英国肾移植登记库的数据。
研究方法：本研究的研究对象为2000年至2015年间在英国移植登记库注册、并随访至2018年5月的所有标准风险肾移植患者。标准风险肾移植的定义为[原文此处内容缺失]：
研究结果：本研究共纳入3597例肾移植患者，分为两组：诱导治疗组（n=2858），即接受IL-2受体拮抗剂诱导治疗的患者；非诱导治疗组（n=739）。两组患者移植术后1年的估算肾小球滤过率（estimated glomerular filtration rate, eGFR）无显著差异（相关系数=1.224，95%置信区间为-0.347~2.796）。诱导治疗组的平均eGFR为59.922 mL/min/1.73m²，标准差（standard deviation, SD）为29.171；非诱导治疗组的平均eGFR为64.557 mL/min/1.73m²，SD为46.763。两组患者移植术后5年的移植物存活率无显著差异（风险比（hazard ratio, HR）=0.944，95%置信区间为0.599~1.485，p=0.804）；术后5年的患者存活率亦无显著差异（HR=0.809，95%置信区间为0.477~1.372，p=0.433）。
研究结论：在标准风险肾移植人群中，IL-2受体拮抗剂诱导治疗方案对患者术后1年的eGFR水平及术后5年的肾脏与移植物预后均无显著影响。